{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T14:26:59Z","timestamp":1793629619042,"version":"4.5.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["No.2023JJ60515"],"award-info":[{"award-number":["No.2023JJ60515"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-26999-7","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T11:00:29Z","timestamp":1764759629000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A real-world safety analysis of infection-related adverse events associated with belimumab, rituximab, and TNF inhibitors using the FAERS database"],"prefix":"10.1038","volume":"15","author":[{"given":"Wang","family":"Sisi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deng","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huang","family":"Yuting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Rong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liu","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,3]]},"reference":[{"key":"26999_CR1","doi-asserted-by":"publisher","first-page":"E284","DOI":"10.1016\/S2665-9913(23)00091-7","volume":"5","author":"M Rodziewicz","year":"2023","unstructured":"Rodziewicz, M. et al. Early infection risk in patients with systemic lupus erythematosus treated with rituximab or Belimumab from the British Isles lupus assessment group biologics register (BILAG-BR): a prospective longitudinal study. LANCET Rheumatol. 5, E284\u2013E292. https:\/\/doi.org\/10.1016\/S2665-9913(23)00091-7 (2023).","journal-title":"LANCET Rheumatol."},{"key":"26999_CR2","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1093\/toxsci\/kfj148","volume":"91","author":"WG Halpern","year":"2006","unstructured":"Halpern, W. G. et al. Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: Pharmacokinetic, pharmacodynamic, and toxicologic effects. Toxicol. Sci. 91, 586\u2013599. https:\/\/doi.org\/10.1093\/toxsci\/kfj148 (2006).","journal-title":"Toxicol. Sci."},{"key":"26999_CR3","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier, B. et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. 346, 235\u2013242. https:\/\/doi.org\/10.1056\/NEJMoa011795 (2002).","journal-title":"N. Engl. J. Med."},{"key":"26999_CR4","doi-asserted-by":"publisher","unstructured":"Scott, D. L., Wolfe, F. & Huizinga, T. W. J. Rheumatoid arthritis. LANCET 376, 1094\u20131108, (2010). https:\/\/doi.org\/10.1016\/S0140-6736(10)60826-4","DOI":"10.1016\/S0140-6736(10)60826-4"},{"key":"26999_CR5","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1182\/blood-2009-06-225565","volume":"115","author":"D Provan","year":"2010","unstructured":"Provan, D. et al. International consensus report on the investigation and management of primary immune thrombocytopenia. BLOOD 115, 168\u2013186. https:\/\/doi.org\/10.1182\/blood-2009-06-225565 (2010).","journal-title":"BLOOD"},{"key":"26999_CR6","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJMoa1103849","volume":"365","author":"DL Porter","year":"2011","unstructured":"Porter, D. L., Levine, B. L., Kalos, M., Bagg, A. & June, C. H. Chimeric antigen Receptor-Modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725\u2013733. https:\/\/doi.org\/10.1056\/NEJMoa1103849 (2011).","journal-title":"N. Engl. J. Med."},{"key":"26999_CR7","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","volume":"79","author":"JS Smolen","year":"2020","unstructured":"Smolen, J. S. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann. Rheum. Dis. 79, 685\u2013699. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216655 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"26999_CR8","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1002\/art.24403","volume":"60","author":"A Kavanaugh","year":"2009","unstructured":"Kavanaugh, A. et al. Golimumab, a new human tumor necrosis factor \u03b1 Antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis Twenty-Four-Week efficacy and safety results of a Randomized, Placebo-Controlled study. Arthritis Rheum. 60, 976\u2013986. https:\/\/doi.org\/10.1002\/art.24403 (2009).","journal-title":"Arthritis Rheum."},{"key":"26999_CR9","first-page":"1","volume":"10","author":"N Woolacott","year":"2006","unstructured":"Woolacott, N. et al. Etanercept and Infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technol. Assess. 10, 1\u2013 (2006).","journal-title":"Health Technol. Assess."},{"key":"26999_CR10","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1053\/j.gastro.2006.01.048","volume":"130","author":"GR Lichtenstein","year":"2006","unstructured":"Lichtenstein, G. R., Abreu, M. T., Cohen, R. & Tremaine, W. American gastroenterological association Institute technical review on corticosteroids, immunomodulators, and Infliximab in inflammatory bowel disease. GASTROENTEROLOGY 130, 940\u2013987. https:\/\/doi.org\/10.1053\/j.gastro.2006.01.048 (2006).","journal-title":"GASTROENTEROLOGY"},{"key":"26999_CR11","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1136\/annrheumdis-2011-201244","volume":"72","author":"GR Burmester","year":"2013","unstructured":"Burmester, G. R., Panaccione, R., Gordon, K. B., McIlraith, M. J. & Lacerda, A. P. M. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and crohn\u2019s disease. Ann. Rheum. Dis. 72, 517\u2013524. https:\/\/doi.org\/10.1136\/annrheumdis-2011-201244 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"26999_CR12","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1517\/14740338.2015.1009036","volume":"14","author":"G Murdaca","year":"2015","unstructured":"Murdaca, G. et al. Infection risk associated with anti-TNF-\u03b1 agents: a review. Exp. Opin. Drug Saf. 14, 571\u2013582. https:\/\/doi.org\/10.1517\/14740338.2015.1009036 (2015).","journal-title":"Exp. Opin. Drug Saf."},{"key":"26999_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/BTT.S148606","volume":"12","author":"YH Chen","year":"2018","unstructured":"Chen, Y. H. et al. Tuberculosis and viral hepatitis infection in Eastern Europe, Asia, and Latin america: impact of tumor necrosis factor-alpha inhibitors in clinical practice. Biologics: Targets Therapy. 12, 1\u20139. https:\/\/doi.org\/10.2147\/BTT.S148606 (2018).","journal-title":"Biologics: Targets Therapy"},{"key":"26999_CR14","doi-asserted-by":"publisher","first-page":"18509","DOI":"10.1200\/jco.2007.25.18_suppl.18509","volume":"25","author":"S Aksoy","year":"2007","unstructured":"Aksoy, S. et al. Rituximab-induced viral infections in lymphoma patients. J. Clin. Oncol. 25, 18509\u201318509 (2007).","journal-title":"J. Clin. Oncol."},{"key":"26999_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-015-0539-7","author":"MYM Yusof","year":"2015","unstructured":"Yusof, M. Y. M., Vital, E. M. & Buch, M. H. B Cell therapies, approved and emerging: a review of infectious risk and prevention during use. Curr. Rheumatol. Rep. https:\/\/doi.org\/10.1007\/s11926-015-0539-7 (2015).","journal-title":"Curr. Rheumatol. Rep."},{"key":"26999_CR16","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1002\/pds.615","volume":"10","author":"EM Rodriguez","year":"2001","unstructured":"Rodriguez, E. M., Staffa, J. A. & Graham, D. J. The role of databases in drug postmarketing surveillance. Pharmacoepidemiol. Drug Saf. 10, 407\u2013410. https:\/\/doi.org\/10.1002\/pds.615 (2001).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"26999_CR17","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","volume":"13","author":"KJ Rothman","year":"2004","unstructured":"Rothman, K. J., Lanes, S. & Sacks, S. T. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol. Drug Saf. 13, 519\u2013523. https:\/\/doi.org\/10.1002\/pds.1001 (2004).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"26999_CR18","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","volume":"54","author":"A Bate","year":"1998","unstructured":"Bate, A. et al. A bayesian neural network method for adverse drug reaction signal generation. Eur. J. Clin. Pharmacol. 54, 315\u2013321. https:\/\/doi.org\/10.1007\/s002280050466 (1998).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"26999_CR19","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1177\/009286151004400404","volume":"44","author":"W Bunchuailua","year":"2010","unstructured":"Bunchuailua, W. et al. Detection of adverse drug reaction signals in the Thai FDA database: comparison between reporting odds ratio and bayesian confidence propagation neural network methods. DRUG Inform. J. 44, 393\u2013403. https:\/\/doi.org\/10.1177\/009286151004400404 (2010).","journal-title":"DRUG Inform. J."},{"key":"26999_CR20","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1080\/14787210.2018.1544490","volume":"16","author":"M Fernandez-Ruiz","year":"2018","unstructured":"Fernandez-Ruiz, M. & Aguado, J. M. Risk of infection associated with anti-TNF-\u03b1 therapy. EXPERT Rev. ANTI-INFECTIVE THERAPY. 16, 939\u2013956. https:\/\/doi.org\/10.1080\/14787210.2018.1544490 (2018).","journal-title":"EXPERT Rev. ANTI-INFECTIVE THERAPY"},{"key":"26999_CR21","first-page":"119","volume":"17","author":"ES Weiner","year":"1990","unstructured":"Weiner, E. S. & Abeles, M. More on aseptic necrosis and glucocorticoids in systemic lupus erythematosus. J. Rhuematol. 17, 119\u2013119 (1990).","journal-title":"J. Rhuematol."},{"key":"26999_CR22","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41582-020-00427-y","volume":"17","author":"I Cortese","year":"2021","unstructured":"Cortese, I., Reich, D. S. & Nath, A. Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease. Nat. REVIEWS Neurol. 17, 37\u201351. https:\/\/doi.org\/10.1038\/s41582-020-00427-y (2021).","journal-title":"Nat. REVIEWS Neurol."},{"key":"26999_CR23","doi-asserted-by":"publisher","first-page":"4834","DOI":"10.1182\/blood-2008-10-186999","volume":"113","author":"KR Carson","year":"2009","unstructured":"Carson, K. R. et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the research on adverse drug events and reports project. BLOOD 113, 4834\u20134840. https:\/\/doi.org\/10.1182\/blood-2008-10-186999 (2009).","journal-title":"BLOOD"},{"key":"26999_CR24","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s13365-014-0303-1","volume":"21","author":"S Chahin","year":"2015","unstructured":"Chahin, S. & Berger, J. R. A risk classification for immunosuppressive treatment-associated progressive multifocal leukoencephalopathy. J. Neurovirol. 21, 623\u2013631. https:\/\/doi.org\/10.1007\/s13365-014-0303-1 (2015).","journal-title":"J. Neurovirol."},{"key":"26999_CR25","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","volume":"380","author":"R Lozano","year":"2012","unstructured":"Lozano, R. et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. LANCET 380, 2095\u20132128. https:\/\/doi.org\/10.1016\/S0140-6736(12)61728-0 (2012).","journal-title":"LANCET"},{"key":"26999_CR26","doi-asserted-by":"publisher","first-page":"174","DOI":"10.3904\/kjim.2013.28.2.174","volume":"28","author":"KB Chung","year":"2013","unstructured":"Chung, K. B., Lee, E. Y., Im, J. P., Han, S. K. & Yim, J. J. Clinical characteristics and treatment responses of patients who developed tuberculosis following use of a tumor necrosis factor-\u03b1 inhibitor. Korean J. Intern. Med. 28, 174\u2013179. https:\/\/doi.org\/10.3904\/kjim.2013.28.2.174 (2013).","journal-title":"Korean J. Intern. Med."},{"key":"26999_CR27","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab641","author":"SS Katrak","year":"2022","unstructured":"Katrak, S. S. et al. Association of Tumor Necrosis Factor \u03b1 Inhibitor Use with Diagnostic Features and Mortality of Tuberculosis in the United States, 2010\u20132017. OPEN. FORUM Infect. Dis. https:\/\/doi.org\/10.1093\/ofid\/ofab641 (2022).","journal-title":"OPEN. FORUM Infect. Dis."},{"key":"26999_CR28","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1111\/1756-185X.13190","volume":"20","author":"J Tomio","year":"2017","unstructured":"Tomio, J. et al. Tuberculosis screening prior to anti-tumor necrosis factor therapy among patients with immune-mediated inflammatory diseases in japan: a longitudinal study using a large-scale health insurance claims database. Int. J. Rheum. Dis. 20, 1674\u20131683. https:\/\/doi.org\/10.1111\/1756-185X.13190 (2017).","journal-title":"Int. J. Rheum. Dis."},{"key":"26999_CR29","doi-asserted-by":"crossref","unstructured":"Mariette, X., Salmon, D. & Grp, R. French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF-\u03b1 blockers. ANNALS RHEUMATIC DISEASES 62 (2003).","DOI":"10.1136\/ard.62.8.791"},{"key":"26999_CR30","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1016\/S0140-6736(14)60220-8","volume":"384","author":"C Tr\u00e9po","year":"2014","unstructured":"Tr\u00e9po, C., Chan, H. L. Y. & Lok, A. Hepatitis B virus infection. LANCET 384, 2053\u20132063. https:\/\/doi.org\/10.1016\/S0140-6736(14)60220-8 (2014).","journal-title":"LANCET"},{"key":"26999_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15020533","author":"C Shen","year":"2023","unstructured":"Shen, C., Jiang, X., Li, M. & Luo, Y. Hepatitis virus and hepatocellular carcinoma: recent advances. CANCERS https:\/\/doi.org\/10.3390\/cancers15020533 (2023).","journal-title":"CANCERS"},{"key":"26999_CR32","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1053\/j.gastro.2015.06.041","volume":"149","author":"AAGA Amer Gastroenterological","year":"2015","unstructured":"Amer Gastroenterological, A. A. G. A., Hepatitis, B. & Virus Reactivation Guideline. Patient Summary GASTROENTEROLOGY 149, 496\u2013497, doi:https:\/\/doi.org\/10.1053\/j.gastro.2015.06.041 (2015).","journal-title":"Patient Summary GASTROENTEROLOGY"},{"key":"26999_CR33","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1021\/acs.jmedchem.6b00954","volume":"60","author":"W Cho","year":"2017","unstructured":"Cho, W. et al. Treatment of sepsis pathogenesis with high mobility group box protein 1-Regulating Anti-inflammatory agents. J. Med. Chem. 60, 170\u2013179. https:\/\/doi.org\/10.1021\/acs.jmedchem.6b00954 (2017).","journal-title":"J. Med. Chem."},{"key":"26999_CR34","doi-asserted-by":"publisher","first-page":"3253","DOI":"10.1002\/art.11299","volume":"48","author":"KP Baker","year":"2003","unstructured":"Baker, K. P. et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum. 48, 3253\u20133265. https:\/\/doi.org\/10.1002\/art.11299 (2003).","journal-title":"Arthritis Rheum."},{"key":"26999_CR35","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1016\/j.jpeds.2012.11.038","volume":"162","author":"M Kavcic","year":"2013","unstructured":"Kavcic, M. et al. Leveraging administrative data to monitor rituximab use in 2875 patients at 42 freestanding children\u2019s hospitals across the united States. J. Pediatr. 162, 1252\u2013U1226. https:\/\/doi.org\/10.1016\/j.jpeds.2012.11.038 (2013).","journal-title":"J. Pediatr."},{"key":"26999_CR36","doi-asserted-by":"publisher","first-page":"551","DOI":"10.2165\/00002018-200730060-00009","volume":"30","author":"L Reich","year":"2007","unstructured":"Reich, L. Extreme duplication\u2019 in the USFDA adverse events reporting system database. Drug Saf. 30, 551\u2013554. https:\/\/doi.org\/10.2165\/00002018-200730060-00009 (2007).","journal-title":"Drug Saf."},{"key":"26999_CR37","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-025-01956-6","author":"CH Yiu","year":"2025","unstructured":"Yiu, C. H. et al. Comparative effectiveness and safety of biosimilars versus reference biologics in rheumatoid arthritis during treatment initiation: a systematic review of real-world evidence. Int. J. Clin. Pharm. https:\/\/doi.org\/10.1007\/s11096-025-01956-6 (2025).","journal-title":"Int. J. Clin. Pharm."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-26999-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-26999-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-26999-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T13:33:18Z","timestamp":1793626398000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-26999-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,3]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["26999"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-26999-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6638648\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,3]]},"assertion":[{"value":"11 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this Article was revised: The original version of this Article omitted the Funding section. A Funding section has now been added and reads: \u201cThis work was supported by the Hunan Provincial Natural Science Foundation Joint Fund for Drug Administration (No. 2023JJ60515).\u201d The original article has been corrected.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"43048"}}